- BioCryst Pharmaceuticals Inc BCRX reported a first-quarter loss of $0.36, wider than the consensus loss of $0.27 and deeper than the EPS loss of $0.24 reported a year ago mainly driven by higher expenses.
- The company's Q1 sales of $19.10 million beat the consensus estimate of $8.89 million, compared to $4.8 million posted in Q1 of 2020.
- The increase was primarily due to $10.9 million in Orladeyo net revenue generated in the quarter.
- R&D expenses increased around 42% Y/Y to $42.4 million, primarily due to increased investment in the development of BCX9930, its oral Factor D inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria.
- SG&A reached $22.1 million up 39% Y/Y due to higher investment to support the U.S. commercial launch of Orladeyo and expanded international operations.
- Q1 cash and equivalents totaled $244.4 million are expected to support operations into 2023.
- The company did not provide specific revenue or operating expense guidance.
- Price Action: BCRX shares rose 21.1% at $12.93 in the market trading hours on the last check Thursday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.